It is believed that most microbial infections are caused by pathogens organized in biofilms. Recently, it was shown that the dimorphic fungus Histoplasma capsulatum, estimated to be the most common cause of fungal respiratory diseases, is also able to form biofilm. Although the antifungal therapy commonly used is effective, refractory cases and recurrences have been reported. In the search for new compounds with antimicrobial activity, the sesquiterpene farnesol has gained prominence for its antifungal action. This study aimed to evaluate the in vitro susceptibility of H. capsulatum var. capsulatum to the antifungal agents itraconazole and amphotericin B, and farnesol alone and combined, as well as to determine the in vitro antifungal activity of these compounds against biofilms of this pathogen. The results show that farnesol has antifungal activity against H. capsulatum in the yeast and filamentous phases, with MIC values ranging from 0.0078 to 0.00312 mM. A synergistic effect (fractional inhibitory concentration index ¡0.5) between itraconazole and farnesol was found against 100 and 83.3 % of the isolates in yeast and mycelial forms, respectively, while synergism between amphotericin B and farnesol was only observed against 37.5 and 44.4 % of the isolates in yeast and filamentous forms, respectively. Afterwards, the antifungal drugs, itraconazole and amphotericin B, and farnesol alone, and the combination of itraconazole and farnesol, were tested against mature biofilms of H. capsulatum, through XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide) metabolic assay, and the itraconazole and amphotericin B showed lower antibiofilm activity when compared to farnesol alone and farnesol combined with itraconazole. In conclusion, farnesol showed promising results as an antifungal agent against H. capsulatum and also showed adjuvant action, especially when combined with itraconazole, increasing the fungal susceptibility to this drug.
INTRODUCTION
Micro-organisms in biofilms grow in multicellular communities and produce an extracellular matrix that in nature provides a protective niche against aggressive environmental factors such as changes in pH, osmolarity and dehydration, as well as exposure to predators and chemical agents, among others (Mittelman, 1998) . In the host, biofilms have been shown to play a critical role in the development of infection, being considered an important virulence factor (Phillips & Schultz, 2012) . The association in biofilms has a great medical importance as it confers greater resistance to specific mediators of the immune response and increased resistance to antimicrobial agents. This is the main reason why biofilm-associated infections are often refractory to conventional antibiotic therapy (Martinez & Fries, 2010) .
Currently, it is believed that most microbial infections in humans are caused by pathogens organized in biofilms. Therefore, research in mycology has increasingly focused on biofilm phenotyping (Martinez & Fries, 2010) . A wide variety of clinically important fungi have demonstrated the ability to colonize surfaces and form biofilms, including the genera Candida (Ganguly & Mitchell, 2011) , Aspergillus (Müller et al., 2011) , Coccidioides (Davis et al., 2002) , Cryptococcus (Martinez et al., 2008) , Pneumocystis (Cushion et al., 2009) and Trichosporon (Di Bonaventura et al., 2006) . Recently, it was shown that the dimorphic fungus Histoplasma capsulatum, estimated to be the most common cause of fungal respiratory diseases, is also able to form biofilm in vitro (Daher et al., 2007; Pitangui et al., 2012 ).
In addition, a possible association between the ability of H. capsulatum to form biofilms and the pattern of yeast adhesion to epithelial cells was also described. Verstrepen & Klis (2006) emphasized that the ability of biofilm formation is associated with the adhesion property of some fungi. The pattern of infection of H. capsulatum in epithelial cells was characterized as a compact mass of yeast cells, which possibly leads to the formation of a complex three-dimensional architecture of biofilms and promotes the internalization of yeast into host cells. It is believed that this finding could be related to the ability of the H. capsulatum yeasts to avoid the immune system cells (Pitangui et al., 2012) . It is noteworthy that no information on the antifungal susceptibility of H. capsulatum biofilms has been reported.
Histoplasmosis treatment depends on the severity of the disease and risk factors inherent to the patient. In general, the therapy indicated for mild to moderate cases is to prescribe azoles such as itraconazole, while the use of amphotericin B is indicated in serious cases. Although the antifungal therapy commonly used is usually effective, refractory cases and relapses have been described (Wheat et al., 2009) . Many studies have sought new compounds with antimicrobial activity. The sesquiterpene farnesol has gained prominence due to its high antimicrobial activity against bacteria and fungi (Inoue et al., 2004; Jabra-Rizk et al., 2006; Brilhante et al., 2012 Brilhante et al., , 2013 . Its potential antifungal activity has already been demonstrated against different species of Candida and Cryptococcus , as well as against Coccidioides posadasii and Paracoccidioides brasiliensis (Derengowski et al., 2009 ). Given the above, the present study aimed to evaluate the in vitro susceptibility of H. capsulatum var. capsulatum to the antifungals itraconazole and amphotericin B, and the compound farnesol alone and combined, as well as to determine the in vitro antifungal activity of these compounds against H. capsulatum var. capsulatum biofilms.
METHODS
Fungal culture. A total of 18 isolates of H. capsulatum var. capsulatum (18 in filamentous phase and 8 in yeast phase) were included in this study, all belonging to the Fungal Culture Collection of the Specialized Medical Mycology Center (CEMM, Federal University of Ceará). The procedures were performed in a class II biological safety cabinet in a biosafety level 3 laboratory.
Antimicrobial agents. The stock solutions of the tested antimicrobial agents, itraconazole, amphotericin B and farnesol (SigmaAldrich), were prepared with DMSO (Sigma-Aldrich), as solvent, according to the method M27-A3 published by the Clinical and Laboratory Standards Institute (CLSI, 2008) . Subsequently, the solutions were prepared in RPMI 1640 medium with L-glutamine buffered to pH 7.0 with 0.165 M MOPS. The concentration range tested for these drugs alone was from 0.0004 to 0.5 mg ml 21 for itraconazole, from 0.0039 to 2 mg ml 21 for amphotericin B and from 0.0009 to 0.5 mM for farnesol. MIC values obtained with individual drugs were used to determine the highest concentration of these drugs tested in combination. Thus, in combination the concentration ranges varied from ,0.000001 to 0.0625 mg ml 21 for itraconazole, from 0.0009 to 0.5 mg ml 21 for amphotericin B and from 0.00003 to 0.0156 mM for farnesol.
Susceptibility testing
Planktonic form. The strains of H. capsulatum var. capsulatum in filamentous phase were grown on brain heart infusion (BHI) agar and incubated for 7 days at 28 uC. In the yeast phase, the culture was performed on BHI agar supplemented with sheep blood (10 %), with incubation at 35 uC. For both phases, a fungal suspension of each strain was prepared in sterile saline (0.9 %). These suspensions were assessed in a spectrophotometer at 530 nm and adjusted to a transmittance of 90-95 %. They were then diluted 1 : 10 with RPMI 1640 medium buffered with 0.156 M MOPS pH 7.0, to obtain inocula of approximately 0.5610 3 and 2.5610 4 c.f.u. ml 21 (Brilhante et al., 2010) .
The MIC was determined using the broth microdilution method as described in the M27-A3 CLSI standard protocol (CLSI, 2008) . The results were visually obtained, after incubation at 35 uC, for 7 days for the filamentous phase and 4 days for the yeast form. The MIC of amphotericin B alone was regarded as the lowest drug concentration at which no visible fungal growth was detected. For farnesol and the combination of drugs, the MIC was defined as the lowest concentration able to inhibit 80 % of fungal growth, compared to the drug-free control well (Brilhante et al., 2010) . For quality control of antifungal susceptibility testing, Candida parapsilosis ATCC 22019 was used. The interaction between combined drugs was evaluated by calculating the fractional inhibitory concentration index (FICI), according to Odds (2003) , where FICI values ¡0.5 indicate synergism, 0.5,FICI,4.0 indifferent interactions and FICI ¢4.0 antagonism (Odds, 2003) . The antifungal activity was statistically evaluated through ANOVA. P values lower than 0.05 were considered statistically significant.
Biofilm. The test was performed with six H. capsulatum strains in yeast form, based on the protocol described by Pitangui et al. (2012) with slight modifications. Initially, 50 ml fungal suspension in physiological saline with concentrations of 2.4 to 5.5610 6 cells ml 21 was added to the wells of a 96-well flat bottomed plate (TPP). The plates were incubated in an orbital shaker at 80 r.p.m. for 24 h at 35 uC for pre-adhesion of the cells. After this period, the supernatant was removed from each well, and then 200 ml BHI broth was added to each well and the plates were incubated for 7 days under 120 r.p.m. agitation at 35 uC for adhesion and biofilm maturation. After this period, biofilm formation was assessed by measuring the biofilm biomass. The wells were then washed with PBS plus 0.05 % Tween 20, followed by fixation with 100 % methanol. After removing the methanol, the wells were left to dry at room temperature. Afterwards, 0.3 % crystal violet solution was added and incubated for 20 min. The wells were then washed with distilled water and a 33 % solution of acetic acid was added to the previously coloured wells. Subsequently, the content of each plate was transferred to another plate, for immediate spectrophotometric reading at 590 nm. All tests were performed in duplicate and wells containing only BHI broth were included as negative controls in all experiments.
For the biofilm susceptibility assays, the supernatant was removed from the plates containing 7-day-old biofilms and the wells were washed with 200 ml physiological saline. Then, 200 ml of different concentrations of itraconazole, amphotericin B and farnesol were added to the wells, alone and in combination. The tested concentrations for these drugs varied from 1.25 to 100 times greater than the MIC obtained for each of these compounds against H. capsulatum var. capsulatum in the planktonic form. Considering synergism was only observed between itraconazole and farnesol, this was the only combination used against biofilms. The positive controls were performed by adding only BHI broth to the wells of the mature biofilm. The results were obtained after 4 days, following the same incubation parameters mentioned above.
After this period, the metabolic activity of the biofilm was evaluated through metabolic assay with 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT; Sigma). For such, the wells were washed twice with PBS plus 0.05 % Tween 20. Then, 131 ml XTT solution [50 ml sterile PBS, 75 ml XTT and 6 ml menadione (Sigma)] was added to each well and the plates were incubated at 35 uC, for 24 h in the dark, under agitation at 80 r.p.m. Afterwards, the content of each well was transferred to another 96-well plate, which was immediately submitted to spectrophotometric reading at 492 nm. All tests were performed in duplicate and wells containing only BHI broth were included as negative controls in all experiments (Martinez & Casadevall, 2006) . The antifungal activity was statistically evaluated through ANOVA. P values lower than 0.05 were considered statistically significant.
RESULTS

Planktonic form
All strains of H. capsulatum tested were inhibited by sesquiterpene farnesol. The MIC values ranged from 0.0078 to 0.0156 mM for the filamentous phase, and from 0.0078 to 0.0312 mM for the yeast phase. The MIC results showed geometric means of 0.0128 and 0.0165 mM for the filamentous and yeast phases, respectively. Combinations of drugs in subinhibitory doses were also able to inhibit the growth of H. capsulatum. A synergistic effect (FICI ¡0.5) between itraconazole and farnesol was found against 100 % of the isolates in the yeast form and 83.3 % of the isolates in the filamentous form, while between amphotericin B and farnesol synergism was observed against 37.5 % of the isolates in the yeast form and 44.4 % of the isolates in the filamentous form (Table 1 ). In the control strain Candida parapsilosis ATCC 22019 itraconazole showed a MIC of 0.5 mg ml 21 and amphotericin B showed a MIC of 0.03 mg ml
21
.
Biofilm
The metabolic activity of the H. capsulatum biofilms was similarly reduced, when compared to control growth, by all tested compounds at 1006MIC, reaching a reduction of 96.4 % for amphotericin B, 95.3 % for itraconazole, 96.9 % for farnesol, and 96.6 % for the combination of farnesol and itraconazole. However, when the compounds were tested at the lowest concentration (1.256MIC), they presented different inhibitory activity on fungal biofilm. Amphotericin B, for example, caused a 15 % inhibition, and itraconazole caused a 20 % inhibition, while farnesol caused a 96 % inhibition, and the combination of itraconazole and farnesol caused an 80 % inhibition of the metabolic activity of H. capsulatum biofilm (Fig. 1) .
Interestingly, for the growth control and the lower antifungal concentrations, the standard deviation of the biofilm metabolic activity was higher than that observed at higher drug concentrations (Fig. 1) . Considering that the ability to form biofilm is a strain-specific feature, this may be the reason for these observations, since under lower antifungal concentrations, the fungi behave similarly to the growth control.
DISCUSSION
Farnesol acts as a precursor in the biosynthesis of sterols and isoprenoids, which are essential in the regulation of proliferation, differentiation and apoptosis, as well as in lipid biosynthesis, in fungi, plants and animals (Cho et al., 2008; Joo & Jetten, 2010) . In addition, farnesol is a quorum-sensing molecule of Candida albicans, controlling factors such as density, cell morphogenesis (Hornby et al., 2001 ) and biofilm formation (Ramage et al., 2002) . Currently, its potential antifungal effects have been reported against different fungal pathogens Cordeiro et al., 2013) . In this context, the present study evaluated the in vitro inhibitory effect of farnesol against the dimorphic fungus H. capsulatum var. capsulatum.
The results show that farnesol has antifungal activity in vitro against H. capsulatum, in both the filamentous and yeast phases. All isolates tested were inhibited by the compound, with no significant differences between the MIC values obtained for both phases. The MIC range from 0.0078 to 0.00312 mM obtained against H. capsulatum was similar to that reported for another dimorphic fungus, Coccidioides posadasii, ranging from 0.0078 to 0.0616 mM . Furthermore, lower MIC values were observed, when compared to those obtained against the yeast genus Cryptococcus, which ranged from 0.29 to 75 mM , and Candida, which ranged from 9.37 to 150 mM . This observation suggests that farnesol has high inhibitory activity against dimorphic fungi.
We also observed that combinations of farnesol with the antifungals itraconazole and amphotericin B showed a reduction in MIC values when compared to the drugs tested alone. A synergistic effect (FICI ¡0.5) was found between itraconazole and farnesol against 83.3 % of the isolates, while between amphotericin B and farnesol, synergistic interactions were observed against 44.4 % of the isolates. The in vitro synergism between farnesol and antifungals has been previously reported against strains of Coccidioides posadasii and Candida spp. .
Another purpose of this study was to confirm the recent demonstration of the ability of H. capsulatum to form biofilms (Pitangui et al., 2012) . Although a possible association between the ability of the pathogen to form biofilms and the adhesion pattern of yeast H. capsulatum to A549 Antifungal susceptibility of H. capsulatum biofilm epithelial cells has been reported, suggesting that this mechanism may also be related to its ability to suppress the cellular immune system, more studies are needed to better understand the role of this mechanism in the pathogenesis and severity of histoplasmosis (Pitangui et al., 2012) .
The ability of H. capsulatum to form biofilms in polystyrene microplates was explored in the present study; it was shown by analysis of the biomass, through crystal violet staining and the exhibition of metabolic activity, through XTT assay. In addition, the susceptibility of H. capsulatum biofilms to amphotericin B and itraconazole was evaluated, as well as the inhibitory effect of farnesol alone and in combination with itraconazole. For the susceptibility analyses, the metabolic activity of the biofilm cells was evaluated through the XTT reduction assay (Peeters et al., 2008) .
The antifungal drugs and farnesol exhibited inhibitory effects against the biofilm of H. capsulatum. At higher concentrations (506MIC and 1006MIC), the biofilm metabolic activity, measured through XTT assay, was similarly inhibited by antifungal drugs and farnesol, with inhibition percentages ranging from 92.5 to 96.9 %. However, at concentrations lower or equal to 256MIC, the antifungal drugs alone behaved differently from farnesol alone and combined with itraconazole, which caused a more pronounced inhibition of the biofilm metabolic activity. Thus, it was observed that farnesol was effective against H. capsulatum biofilms. This finding corroborates those of Ramage et al. (2002) , who observed that concentrations as low as 300 mM farnesol were able to inhibit Candida albicans biofilm.
Therefore, it can be concluded that farnesol showed promising results in the search for new agents with antifungal activity against H. capsulatum, and it also had adjuvant action, by increasing the susceptibility of this fungus, in planktonic and biofilm growth, to antifungal drugs. This study also contributes to the characterization of the in vitro antifungal susceptibility of H. capsulatum biofilms, but it is still unclear whether the reduced activity of the drugs tested is due to the production of extracellular material or genetic and biochemical alterations in the fungal cells.
